Inhibitory Effects of Gyeji-tang on MMP-9 Activity and the Expression of Adhesion Molecules in IL-4- and TNF-α-Stimulated BEAS-2B Cells

Yu Jin Kim, Woo-Young Jeon, Youn-Hwan Hwang * and Mee-Young Lee *

Herbal Medicine Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 34054, Korea; jinjin0228@kiom.re.kr (Y.J.K.); ssamggun85@kiom.re.kr (W.-Y.J.)
* Correspondence: hyhhwang@kiom.re.kr (Y.H.H.); cozy11@kiom.re.kr (M.-Y.L.); Tel.: +82-42-868-9260 (Y.H.H.); Tel.: +82-42-868-9356 (M.-Y.L.)

Abstract: Gyeji-tang (GJT), a traditional herbal formula composed of five herbal medicines, is commonly used to treat the common cold, exogenous febrile disease, fever and headaches in Korea, China and Japan. Although various pharmacological activities of GJT have been reported in several studies, the effect of GJT water extract (GJTWE) on airway inflammation has not yet been investigated. This study aimed to evaluate the effects of GJTWE on airway inflammation-related factors using human bronchial epithelial BEAS-2B cells, and to identify the phytochemicals in GJTWE by ultra-performance liquid chromatography-diode array detector-tandem mass spectrometry (UPLC-DAD-MS/MS) analysis. GJTWE significantly decreased the production of chemokines, including eotaxin-3, eotaxin-1, regulated on activation normal T-cell expressed and secreted (RANTES), and matrix metalloproteinase-9, and the expression of the adhesion molecules, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, in interleukin-4 + tumor necrosis factor-α (IT)-stimulated BEAS-2B cells. In the UPLC-DAD-MS/MS analysis, 21 phytochemicals, including six flavonoids, two chalcones, five terpenoids, six phenolics, one phenylpropanoid and one coumarin, were identified in GJTWE. The findings suggested that GJTWE might exhibit anti-inflammatory effects on airway inflammation by regulating the expression of inflammatory response-related factors in IT-stimulated BEAS-2B cells; further studies are required to determine the bioactive compounds involved in the inhibition of airway inflammation.

Keywords: Gyeji-tang; airway inflammation; BEAS-2B cells; eotaxins; RANTES; matrix metalloproteinase-9; UPLC-DAD-MS/MS

1. Introduction

Airway inflammation is an important factor in the pathogenesis of obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease [1]. The inflammatory response of the airway epithelium, mediated by the increased expression of chemokines, cytokines, inflammatory enzymes, and adhesion molecules, involves the recruitment, activation, and infiltration of inflammatory cells, along with the tissue remodeling of airways [1,2]. The bronchial epithelium plays a central role in regulating the airway inflammatory response [3]. The human bronchial epithelial BEAS-2B cells stimulated by interleukin (IL)-4, tumor necrosis factor (TNF)-α, or lipopolysaccharide have been reported to secrete chemokines and cytokines such as eotaxin-1, eotaxin-3, regulated on activation normal T-cells expressed and secreted (RANTES), and IL-8, which contribute to airway inflammation [4–6]. In addition, BEAS-2B cells treated with IL-4 and TNF-α increase the expression of matrix metalloproteinase (MMP)-9, an important proteolytic enzyme that induces bronchial remodeling in asthma [4]. Tissue remodeling in the airways may cause airway hyperresponsiveness, and may reduce the reversibility of the airflow.

Citation: Kim, Y.J.; Jeon, W.-Y.; Hwang, Y.-H.; Lee, M.-Y. Inhibitory Effects of Gyeji-tang on MMP-9 Activity and Expression of Adhesion Molecules in IL-4- and TNF-α-Stimulated BEAS-2B Cells. Plants 2021, 10, 951. https://doi.org/10.3390/plants10050951

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
obstruction in asthma [5]. The accumulation of leukocytes in the inflamed sites of the airways is a hallmark of asthma, and the infiltration of inflammatory cells occurs through the expression of adhesive molecules that regulate the adhesion of leukocytes and epithelial cells [7]. The expression of adhesion molecules, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) has been reported to be induced by cytokines in human bronchial epithelial cells [8]. Therefore, suppressing the production, expression, and activation of cytokines, chemokines, inflammatory enzymes, and adhesion molecules in bronchial epithelial cells may help relieve airway inflammation.

Gyeji-tang (GJT), alternatively called Gui-Zhi-Tang in China and Keishi-to in Japan, is one of the traditional herbal formulae in Shang-Han-Lun, and has been widely used to treat the common cold, exogenous febrile disease, fever, headache, and inflammation [9–11]. GJT is comprised of five herbs: *Cinnamomum cassia* Blume (twig), *Paeonia lactiflora* Pall. (root), *Glycyrrhiza uralensis* Fisch. (root and rhizome), *Zingiber officinale* Rosc. (rhizome), and *Ziziphus jujuba* Mill. (fruit). The pharmacological effects of GJT had been reported previously. It exhibits antipyretic effects by attenuating bradykinin-induced prostaglandin E2 (PGE2) release from rabbit aortic smooth muscle cells [12], anti-inflammatory effects by blocking extracellular signal-regulated kinase (ERK) and nuclear factor kappa-B (NF-kB) signaling pathways in lipopolysaccharide-stimulated RAW 264.7 cells [13], and immunosuppressive effects by inhibiting IL-2 production in murine spleen cells [13]. In addition, animal studies have demonstrated the administration of GJT to ameliorate impairments in sociability, spatial attention, and fear memory deficits by restoring neuronal functions [14], and that it is effective in chronic pancreatitis caused by pancreatic ischemia [15]. Despite the various reported pharmacological activities of GJT, their effects on airway inflammation have not yet been investigated. The present study aimed to explore the effects of GJT on airway inflammation-related factors, such as eotaxin-3, eotaxin-1, RANTES, MMP-9, ICAM-1, and VCAM-1, in the human bronchial epithelial BEAS-2B cell line. In addition, the phytochemicals of GJTWE were identified using ultra-performance liquid chromatography-diode array detector-tandem mass spectrometry (UPLC-DAD-MS/MS) analysis.

2. Results

2.1. UPLC-DAD-MS/MS Analysis of GJTWE

In order to identify the phytochemicals in GJTWE, UPLC-DAD-MS/MS analysis was performed. The chromatographic separation of the compounds in GJTWE was achieved on an Acquity BEH C18 column (100 × 2.1 mm, 1.7 μm, Waters) at 40 °C for 20 min, with mobile phases consisting of 0.1% (v/v) formic acid in water and acetonitrile. Both the positive and negative ion modes were used to acquire the MS spectra of each compound. In total, 21 compounds, namely protocatechuic acid, protocatechualdehyde, syringaldehyde, cinnamaldehyde, and coumarin from *C. cassia* [16]; albiflorin, paeoniflorin, benzoylpaenolinorin, 1,2,3,4,6-O-pentagalloylgucose, and catechin from *P. lactiflora* [17]; schaftoside, liquiritin apioside, liquiritin, liquiritigenin, isoliquiritin, isoliquiritigenin, glycyrhrizin, and glycyrrhetinic acid from *G. uralensis* [17]; 6-gingerol and 6-shogaol from *Z. officinale* [18]; and isovitexin from *Z. jujuba* [19], were identified. The detailed MS data are listed in Table 1. The retention times, precursor ions, and MS/MS fragments of each compound were compared to those of the reference standards. Flavonoids and chalcones were more suitably ionized in the negative ion mode, while most terpenoids, coumarins, and other phenolic compounds were detected in the positive ion mode. The UV pattern at 250 nm and the base peak chromatograms in the positive and negative ion modes of GJTWE are shown in Figure 1a, and the extracted ion chromatograms for each compound are presented in Figure 1b.
Table 1. Phytochemicals identified from GJTWE by UPLC-DAD-MS/MS.

| No. | Rt (min) | Calculated (m/z) | Measured (m/z) | Adduct | Error (ppm) | Formula | MS/MS (m/z) | Identifications                  |
|-----|----------|------------------|----------------|---------|-------------|----------|-------------|----------------------------------|
| 1   | 4.32     | 153.0193         | 153.0187       | [M−H]−  | −3.9699     | C7H6O4   | 153.0176, 109.0276 | Protocatechuic acid [16]         |
| 2   | 5.09     | 139.0390         | 139.0389       | [M+H]+  | −0.5419     | C7H6O3   | 139.0388, 121.0285, 111.0443, 93.0340 | Protocatechualdehyde [16]        |
| 3   | 5.16     | 289.0718         | 289.0710       | [M−H]−  | 3.5430      | C15H14O6 | 289.0709, 203.0701, 179.0491, 165.0176, 137.0228 | Catechin [17]                   |
| 4   | 5.93     | 563.1406         | 563.1392       | [M−H]−  | −2.5017     | C26H28O14 | 563.1381, 473.1062, 443.0975, 383.0745, Schaftoside [17] | | 353.0655                         |
| 5   | 6.04     | 481.1704         | 481.1698       | [M+H]+  | −1.3305     | C23H28O11 | 179.0700, 151.0752, 133.0648 | Albiflorin [17]                |
| 6   | 6.28     | 525.1614         | 525.1634       | [M+HC\textsubscript{O}2]− | 3.8676 | C23H28O11 | 327.1074, 165.0541, 121.0277 | Paoniflorin [17]           |
| 7   | 6.67     | 433.1129         | 433.1126       | [M+H]+  | −0.7161     | C21H20O10 | 433.1061, 415.1018, 397.0916, 379.0807, 351.0856, 313.0702 | Isovitexin [19]                 |
| 8   | 6.73     | 549.1614         | 549.1637       | [M−H]−  | 4.2543      | C23H28O13 | 549.1605, 417.1173, 255.0652, 135.0069, 119.0487 | Liquiritin apioside [17]        |
| 9   | 6.85     | 183.0652         | 183.0652       | [M+H]+  | −0.1077     | C8H8O4   | 183.0652, 123.0442 | Syringaldehyde [16]            |
| 10  | 6.87     | 417.1191         | 417.1182       | [M−H]−  | −2.2678     | C11H8O4  | 417.1183, 255.0653, 135.0070, 119.0483 | Liquiritin [17]                |
| No. | Rt  | M/z         | M/z (min) | Compounds and Properties |
|-----|-----|-------------|-----------|--------------------------|
| 11  | 7.01| 939.1109, 939.1087 [M−H]− | −2.3388 C_{26}H_{32}O_{26} | 769.0862, 617.0756, 1,2,3,4,6-O-Penta-O-galloylglucose (10) |
|     |     | 471.3469, 471.3463 [M+H]+ | 4.0361 C_{30}H_{62}O_{16} | 471.3464, 407.3315, Glycyrrhetinic acid (17) |
| 12  | 8.65| 417.1191, 417.1183 [M−H]− | 4.0974 C_{21}H_{22}O_{9} | 147.0439, 103.0547, (17) |
|     |     | 147.0441, 147.0439 [M+H]+ | −0.9875 C_{9}H_{6}O_{2} | 147.0439, 103.0547, Coumarin (16) |
| 13  | 8.80| 147.0441, 147.0439 [M+H]+ | 0.0089 C_{9}H_{8}O | 133.0648, 115.0544, (17) |
|     |     | 147.0441, 147.0439 [M+H]+ | 0.9875 C_{9}H_{6}O_{2} | 147.0439, 103.0547, Coumarin (16) |
| 14  | 9.28| 255.0663, 255.0659 [M−H]− | −2.7953 C_{15}H_{12}O_{4} | 255.0651, 153.0180, Liquiritigenin (17) |
| 15  | 10.84| 629.1876, 629.1867 [M+HCO_{2}]− | −2.1643 C_{30}H_{62}O_{16} | 821.3943, 135.0180, Benzoylpaeoni florin (17) |
|     |     | 317.1720, 317.1720 [M+Na]+ | −0.9535 C_{17}H_{20}O_{4} | 317.1690, 299.1064, 6-Gingerol (18) |
| 17  | 12.02| 255.0663, 255.0671 [M−H]− | 3.1272 C_{15}H_{20}O_{4} | 255.0652, 153.0180, Isoliquiritigenin (17) |
| 18  | 13.18| 821.3965, 821.3999 [M−H]− | 4.1300 C_{18}H_{20}O_{4} | 821.3943, 135.0180, Glycyrrhizin (17) |
| 19  | 14.52| 317.1723, 317.1720 [M+Na]+ | −0.9535 C_{17}H_{20}O_{4} | 317.1690, 299.1064, 6-Gingerol (18) |
| 20  | 17.68| 277.1798, 277.1809 [M+H]+ | 4.0361 C_{17}H_{20}O_{4} | 277.2159, 259.2050, 6-Shogaol (18) |
| 21  | 19.02| 471.3469, 471.3463 [M+H]+ | −1.2879 C_{30}H_{62}O_{16} | 471.3464, 407.3315, Glycyrrhetinic acid (17) |

1 Rt: retention time (min).
2.2. Cytotoxicity of GJTWE in BEAS-2B Cells

In order to determine the cytotoxicity of the test materials in BEAS-2B cells, the latter were exposed to various concentrations of GJTWE for 24 h. The cell viability was measured subsequently using a cell counting kit (CCK)-8 assay. GJTWE did not produce any significant cytotoxic effect at any concentration. Non-toxic concentrations (≤ 500 μg/mL) of the test materials were used for the subsequent experiments (Figure 2).

Figure 2. Cytotoxic effects of GJTWE in BEAS-2B cells. BEAS-2B cells were seeded into 96-well plates and treated with various concentrations (31.25, 62.5, 125, 250, and 500 μg/mL) of GJTWE for 24 h. The cell viability was assessed using a CCK-8 kit. The values are expressed as the mean ± SEM.
2.3. Effect of GJTWE on Chemokine Production

The effects of GJTWE on eotaxin-3, eotaxin-1, and RANTES production were assessed in IT-stimulated BEAS-2B cells. The production of eotaxin-3, eotaxin-1, and RANTES was significantly increased upon IL-4 + TNF-α (IT) stimulation compared to that in the vehicle-treated cells (p < 0.01). However, GJTWE significantly decreased the production of chemokines, such as eotaxin-3, eotaxin-1, and RANTES, in a dose-dependent manner (p < 0.05, p < 0.01, Figure 3a–c).

![Figure 3](image)

**Figure 3.** Effects of GJTWE on the production of chemokines in BEAS-2B cells. The cells were preTable 125, 250, and 500 µg/mL) and then co-stimulated with IL-4 + TNF-α (IT, 50 ng/mL) for 48 h. The levels of h-eotaxin-3 (a), h-eotaxin-1 (b), and h-RANTES (c) released into the culture medium were assessed using commercially available ELISA kits. The values are expressed as the mean ± SEM. "p < 0.01 versus vehicle-treated cells and "p < 0.05 or "p < 0.01 versus IT-treated cells.

2.4. Effect of GJTWE on MMP-9 Activity

In order to identify the regulator of inflammatory processes, we determined the activities of MMP-9 and MMP-2 in IT-stimulated BEAS-2B cells. As shown in Figure 4a, MMP-9 activity was remarkably increased by the IT treatment. However, GJTWE greatly reduced the MMP-9 activity in a dose-dependent manner. The relative ratio of MMP-9/MMP-2 was significantly increased in the IT-treated cells compared to that in the vehicle-treated cells (p < 0.01). In contrast, GJTWE significantly decreased the relative ratio of MMP-9/MMP-2 compared to that in the IT-treated cells (p < 0.01, Figure 4b).

![Figure 4](image)

**Figure 4.** Effects of GJTWE on the activity of MMP-9 in BEAS-2B cells. The cells were pretreated with GJTWE (125, 250, and 500 µg/mL) and then co-stimulated with IL-4 + TNF-α (IT, 50 ng/mL) for 48 h. The cell supernatants were loaded for gelatin zymography. Representative photographs of the MMP-9 activity (a) and MMP-9/MMP-2 band intensities (b) are shown. The values are expressed as the mean ± SEM. "p < 0.01 versus vehicle-treated cells and "p < 0.01 versus IT-treated cells.
2.5. Effect of GJTWE on the Expression of Adhesion Molecules

In order to identify the indicators of inflammatory responses, we determined the ICAM-1 and VCAM-1 expression in the IT-stimulated BEAS-2B cells. As shown in Figure 5a and 5b, the ICAM-1 and VCAM-1 expression was remarkably increased by the IT treatment. However, GJTWE dramatically decreased the ICAM-1 and VCAM-1 expression in a dose-dependent manner. The relative ratios of ICAM-1/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and VCAM-1/GAPDH were significantly increased in the IT-treated cells compared to the vehicle-treated cells (p < 0.01). In contrast, GJTWE significantly reduced the relative ratios of ICAM-1/GAPDH and VCAM-1/GAPDH compared to that in the IT-treated cells (p < 0.01, Figure 5c and 5d).

![Figure 5. Effects of GJTWE on the expression of adhesion molecules in BEAS-2B cells.](image)

Figure 5. Effects of GJTWE on the expression of adhesion molecules in BEAS-2B cells. The cells were pretreated with GJTWE (125, 250, and 500 μg/mL) and then co-stimulated with IL-4 + TNF-α (IT, 50 ng/mL) for 48 h. The total RNA was isolated, and RT-PCR was performed in order to analyze the expression of ICAM-1 and VCAM-1 at the mRNA level. Representative photographs of the ICAM-1 (a) or VCAM-1 (b) expression, and the band intensities of ICAM-1/GAPDH (c) or VCAM-1/GAPDH (d) are shown. The values are expressed as the mean ± SEM. *p < 0.01 versus vehicle-treated cells and **p < 0.01 versus IT-treated cells.

3. Discussion

The human bronchial epithelial cell line, BEAS-2B, has been previously used to examine cytokine- or endotoxin-associated airway inflammation, which may induce allergic asthma [20,21]. Chemokines from bronchial epithelial cells have also been reported to contribute to chronic airway inflammation by recruiting inflammatory cells [22]. Eotaxins are members of the CC chemokine family, which are potent attractants of eosinophils and might contribute to airway inflammation. Eotaxins represent a group of chemokines consisting of three sets of subtypes: eotaxin-1 (CC chemokine ligand [CCL]-11) [23], eotaxin-2 (CCL24) [24], and eotaxin-3 (CCL26) [25]. Most importantly, eotaxin-3 is a more effective chemoattractant than eotaxin-1 and eotaxin-2 for eosinophils in patients with asthma [26]. RANTES (CCL5) is a chemotactic and activating factor for eosinophils, and a candidate mediator in asthma. It is able to attract several types of inflammatory cells, including eosinophils, monocytes, and T helper (Th) cells, to the site of inflammation [27]. Our current findings demonstrated that GJTWE could significantly reduce the increased production of CC chemokines, including eotaxin-3, eotaxin-1, and RANTES, in IT-stimulated BEAS-2B cells.
MMPs are enzymes that degrade the extracellular matrix and basement membrane, and regulate the infiltration of inflammatory cells; consequently, they participate in tissue remodeling [28]. MMP-9 and MMP-2, members of the gelatinase family of MMPs, are recognized to play important roles in the turnover and degradation of extracellular matrix proteins during cellular recruitment in inflammation [29]. Whereas MMP-2 is constitutively expressed in many cell types, MMP-9 is strongly induced in airway epithelial cells by inflammatory cytokines, particularly TNF-α [30,31]. Thus, the relative expression levels of MMP-9 were normalized to those of MMP-2. Our current findings indicate that GJTWE significantly decreases the MMP-9 activity in IT-stimulated BEAS-2B cells.

The upregulation of adhesion molecules on the surface of respiratory epithelial cells is an important factor in the development of asthma. The infiltration of inflammatory cells mostly results from the enhanced adhesion of leukocytes to epithelial cells via the expression of adhesion molecules [32]. Members of the immunoglobulin superfamily of endothelial adhesion molecules, ICAM-1 and VCAM-1, play an important role in inflammatory cell infiltration into inflamed airways [33]. The current results demonstrated that treatment with GJTWE significantly suppresses the increased expression of adhesion molecules, including ICAM-1 and VCAM-1, in IT-stimulated BEAS-2B cells. Taken together, the findings demonstrated that the administration of GJTWE has anti-inflammatory activity, at least via the downregulation of CC chemokine expression and MMP-9 activity, resulting in the reduced expression of adhesion molecules in IT-stimulated BEAS-2B cells.

GJT is composed of five herbal medicines, and the effects of the individual herbs on airway inflammation-related diseases, such as asthma and bronchitis, has been reported earlier. C. cassia protects airway epithelia from human respiratory syncytial virus [34]. P. lactiflora was shown to improve allergic asthma in a mouse model by inhibiting Ca2+ influx-dependent mast cell degranulation [35]. G. uralensis was reported to reduce the airway responsiveness in patients with asthma [36], and Z. officinale ameliorated allergic airway inflammation by suppressing the Th2-mediated immune response [37]. Z. jujuba also exhibits potent anti-asthmatic activity [38].

The main ingredients of GJT include phenylpropanoids (e.g., cinnamaldehyde and cinnamic acid), terpenoids (e.g., albiflorin, paeoniflorin, benzoyl paeoniflorin, and glycyrrhizin), flavonoids (e.g., liquiritin, liquiritigenin, and liquiritin apioside), chalcones (e.g., isoliquiritin and isoliquiritigenin), and phenolic compounds (e.g., 6-gingerol and 6-shogaol) [10,11]. In this study, UPLC-DAD-MS/MS analysis was performed in order to confirm the phytochemicals of GJTWE, and 21 compounds—including six flavonoids (catechin, schaftoside, isovitexin, liquiritin apioside, liquiritin, and liquiritigenin), two chalcones (isoliquiritin and isoliquiritigenin), five terpenoids (albiflorin, paeoniflorin, benzoyl paeoniflorin, glycyrrhizin, and glycyrrhetinic acid), six phenolics (protocatechuic acid, protocatechualdehyde, syringaldehyde, 1,2,3,4,6-pentagalloylglucose, 6-gingerol, and 6-shogaol), one phenylpropanoid (cinnamaldehyde), and one coumarin (coumarin)—were identified.

Several studies have previously reported the effects of various compounds contained in the herbal composition of GJT on airway inflammation-related diseases. Paeoniflorin is known to exhibit anti-asthmatic effects by inhibiting the abnormal proliferation and migration of airway smooth muscle cells, and by modulating the Th1/Th2 equilibrium [39,40]. Glycyrrhizin has been reported to reduce airway inflammation in vivo [41], and to ameliorate the progression of asthma and long-term chronic histopathological changes in the lungs of a mouse model of asthma [42,43]. In addition, jujuboside B, 6-shogaol and 6-gingerol exhibited potent anti-asthmatic effects in a murine asthma model by regulating an exaggerated inflammatory response, improving airway hyperresponsiveness, and suppressing airway inflammation [38,44,45]. The previous studies and our current data collectively suggest that the anti-inflammatory activity of GJTWE in IT-stimulated BEAS-2B cells may be due to a synergistic effect between several of the compounds of GJTWE. Further investigations are needed to clarify their mechanisms of action by identifying the
phytochemicals and their contribution to the efficacy of GJTWE through quantitative analysis in detail.

In conclusion, GJTWE inhibited the production of chemokines, such as eotaxin-3, eotaxin-1 and RANTES, and reduced the MMP-9 activity and expression of adhesion molecules ICAM-1 and VCAM-1 in IT-stimulated BEAS-2B cells. Therefore, our results revealed that GJTWE might exhibit anti-inflammatory effects on airway inflammation by suppressing the expression of inflammatory response-related factors. Moreover, 21 phytochemicals were confirmed in GJTWE by UPLC-DAD-MS/MS analysis. Further studies would be required to determine the bioactive compounds that inhibit airway inflammation.

4. Materials and Methods

4.1. Materials and Reagents

The GJTWE was provided by the Herbal Medicine Research Division, Korea Institute of Oriental Medicine (Daejeon, South Korea). The detailed extraction method of GJTWE was described in a previous paper [12]. The 21 reference standards (purity > 95%) used to identify the phytochemicals in GJTWE were purchased from TargetMol (Boston, MA, USA), with the exception of liquiritin apioside, alibiflorin, and protocatechuic acid (ChemFaces, Wuhan, China). LC-MS-grade water, acetonitrile, methanol, and formic acid were obtained from Thermo Fisher Scientific (Waltham, MA, USA).

4.2. Cell Culture

The human bronchial epithelial cell line BEAS-2B was obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA). The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco Inc., New York, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco Inc.), penicillin (100 U/mL, Gibco Inc.), and streptomycin (100 μg/mL, Gibco Inc.) at 37 °C in an atmosphere of 5% CO2/95% air under saturating humidity.

4.3. Cytotoxicity Assay

The cell viability was assessed using a cell CCK-8 assay (Dojindo, Kumamoto, Japan) according to the manufacturer’s instructions. BEAS-2B cells (6 × 10^4 cells/well) were incubated in 96-well plates with various concentrations (31.25, 62.5, 125, 250, and 500 μg/mL) of GJTWE for 24 h. CCK-8 reagent was added to each well and incubated for 4 h. The absorbance was measured at 450 nm using a Benchmark Plus microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). The percentage of cell viability was calculated using the following formula: cell viability (%) = (mean absorbance in the test sample wells/mean absorbance in the vehicle-treated control wells) × 100.

4.4. Cell Stimulation

BEAS-2B cells (5 × 10^5 cells/well) were cultured in 6-well plates in a medium containing 10% FBS. After having reached confluence, the cells were washed and incubated with 1 mL serum-free medium containing 50 ng/mL IT (R&D Systems Inc., Minneapolis, MN, USA) to produce eotaxin-3, eotaxin-1, RANTES, MMPs, and adhesion molecules for 48 h.

4.5. Measurement of Chemokine Production

Culture supernatants were used to measure the production of eotaxin-3, eotaxin-1, and RANTES using an enzyme-linked immunosorbent assay (ELISA) protocol from R&D Systems Inc. (Minneapolis, MN, USA), according to the manufacturer’s instructions (Catalog No. DY278, DY320 and DY346). The absorbance was measured at 450 nm using a Benchmark Plus microplate reader (Bio-Rad Laboratories, Hercules, CA, USA).
4.6. Measurement of MMP-9 Activity

The MMP-9 activity was measured by gelatin zymography. The cell supernatant was mixed with 5× non-reducing sample buffer (Fermentas Inc., Pittsburg, PA, USA) before being loaded onto a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis setup (SDS-PAGE; Bio-Rad Laboratories, Hercules, CA, USA) containing 1% gelatin as an MMP substrate. The samples were subjected to electrophoresis at 80 V for 2 h. Following the electrophoresis, the gels were washed twice in 2.5% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) for 1 h to remove the SDS, and then incubated for 16 h at 37 °C in developing buffer (1 M Tris-HCl, pH 7.5, 10 mM CaCl2). Following incubation, the gels were stained with Coomassie Brilliant Blue G (Sigma-Aldrich, St. Louis, MO, USA) for 35 min, de-stained in 25% methanol and 8% acetic acid solution for 20 min, and finally rinsed twice with de-staining solution in order to visualize the digested bands in the gelatin matrix. The gelatinase activity was manifested as white bands on a blue background, representing areas of proteolysis of the substrate protein. The relative expression levels of the MMP-9 were normalized to those of MMP-2. Images of the gels were collected, and the average of the band intensities was measured using the commercially available ChemiDoc™ XRS+ imaging system (Bio-Rad Laboratories, Hercules, CA, USA).

4.7. Measurement of the Adhesion Molecule Expression

The total ribonucleic acid (RNA) was isolated using a TRIzol reagent according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). One microgram of total RNA was converted to complementary deoxyribonucleic acid (cDNA) using an iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA) containing oligo-dT primers, and diethyl pyrocarbonate-treated water was added to make a final volume of 20 μL; it was incubated at 42 °C for 30 min thereafter. The polymerase chain reaction (PCR)-based amplification used gene-specific primers for ICAM-1 (forward, 5'-AGG CCT TAT TCC TCC CTT CC-3'; reverse, 5'-TCA CTG CAG GAA ACT GGA GC-3'), VCAM-1 (forward, 5'-CAT TGA CTT GCA GCA CCA CA'; reverse, 5'-TCC AGC CTG TCA AAT GGG TA-3'), and GAPDH (forward, 5'-GTG ATG GCA TGG ACT GTG GT-3'; reverse, 5'-AAG GGT CAT CAT CTC TGC CC-3'). The reverse transcription (RT)-PCR reaction mixture was comprised of 1 μL cDNA and 1.56 μL Taq PCR master mix (EPIIS biotech, Daejeon, Republic of Korea), which contained 1.5 mM MgCl2, 0.1 M of each forward and reverse primer, and 7.44 μL water in a final volume of 10 μL. The PCR reaction was comprised of 22 cycles of denaturation at 94 °C for 30 s, annealing at 55 °C for 1 min, and extension at 72 °C for 1 min 30 s for ICAM-1; 29 cycles of denaturation at 94 °C for 30 s, annealing at 55 °C for 1 min, and extension at 72 °C for 1 min 30 s for VCAM-1; and 25 cycles of denaturation at 94 °C for 30 s, annealing at 52 °C for 1 min, and extension at 72 °C for 1 min 30 s for GAPDH. Each reaction was performed in a Bio-Rad MyCycler™ Thermal Cycler (Bio-Rad Laboratories). The relative ratio of ICAM-1 and VCAM-1 expression was adjusted based on the expression of GAPDH as a control. This assay was performed in triplicate. The amplified products were separated on a 1.5% agarose gel and visualized using loading STAR staining (Dynebio, Seongnam, Korea). The images were captured and analyzed using the ChemiDoc™ XRS+ imaging system (Bio-Rad Laboratories, Hercules, CA, USA).

4.8. UPLC-DAD-MS-MS Analysis of GJTWE

GJTWE was dissolved in methanol up to a concentration of 20 mg/mL and filtered using a syringe filter (0.2-μm pore size). The standards were prepared in methanol at a final concentration of 10 μg/mL for the UPLC-DAD-MS/MS analysis. The 21 phytochemicals in GJTWE were analyzed using a Dionex UltiMate 3000 system equipped with a Thermo Q-Exactive mass spectrometer according to the previously reported methods [46]. An Acquity BEH C18 column (100 × 2.1 mm, 1.7 μm, Waters Corp., Milford, MA, USA),
maintained at 40 °C, was used to separate the compounds in GJT. The mobile phases consisted of 0.1% (v/v) formic acid in water (A) and acetonitrile (B). Gradient elution was performed with a flow rate of 0.25 mL/min, as follows: 0–1 min, 3% B; 1–2 min, 3–15% B; 2–13 min, 15–50% B; 13–20 min, 50–100% B; 20–23 min, 100% B; and 23.5–27.5 min, 3% B. The injection volume was 3 µL for analysis. The MS analysis was conducted with an electrospray ionization source in both positive and negative ionization modes using a Q-Exactive mass spectrometer. The MS spectra were acquired in full MS-ddMS² mode. The optimized MS/MS conditions were as follows: ion spray voltage, 3.8 kV; capillary temperature, 320 °C; sheath gas pressure, 40 arbitrary units (au); auxiliary gas pressure, 10 au; S-lens RF level, 60; resolution, 70000 (full MS) and 17500 (ddMS²); scan range, 100–1500 m/z; and normalized collision energy, 25 eV. All of the data were acquired and processed using Xcalibur v.3.0 and TraceFinder v.3.2 software (Thermo Fisher Scientific, Bremen, Germany).

4.9. Statistical Analyses
All of the data are presented as the mean ± standard error of the mean (SEM). The statistical significance was determined using analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test. Statistical significance was set at p < 0.05 or < 0.01.

Author Contributions: Conceptualization, Y.-H.H. and M.-Y.L.; investigation, Y.J.K. and W.-Y.J.; writing—original draft preparation, Y.J.K. and W.-Y.J.; writing—review and editing, Y.-H.H. and M.-Y.L.; supervision, M.-Y.L.; funding acquisition, M.-Y.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Korea Institute of Oriental Medicine, grant number KSN2021220.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available within the article.

Acknowledgments: We thank the Herbal Medicine Research Division, Korea Institute of Oriental Medicine for the kind donation of the plant material.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Barnes, P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 2008, 8, 183–192, doi:10.1038/nri2254.
2. Holgate, S.T.; Lackie, P.; Wilson, S.; Roche, W.; Davies, D. Bronchial epithelium as a key regulator of airway allergen sensitization and remodeling in asthma. Am. J. Respir. Crit. Care Med. 2000, 162, S113–S117, doi:10.1164/ajccm.162.supplement_2.ras-12.
3. Verheggen, M.M.; van Hal, P.T.; Adriaansen-Soeting, P.W.; Goense, B.J.; Hoogsteden, H.C.; Brinkmann, A.O.; Versnel, M.A. Modulation of glucocorticoid receptor expression in human bronchial epithelial cell lines by IL-1 beta, TNF-alpha and LPS. Eur. Respir. J. 1996, 9, 2036–2043, doi:10.1183/09031936.96.09102036.
4. Kim, J.H.; Jeon, W.Y.; Lee, M.Y.; Seo, C.S.; Lim, H.S.; Shin, H.K. Inhibitory activity of Socheongryong-tang and its constituent components against the production of RANTES, eotaxin, eotaxin-3 and MMP-9 from BEAS-2B cells. Mol. Med. Rep. 2014, 10, 3035–3046, doi:10.3892/mmr.2014.2637.
5. Takeda, N.; Sumi, Y.; Préfontaine, D.; Al Abri, J.; Al Healy, N.; Al-Ramli, W.; Michoud, M.C.; Martin, J.G.; Hamid, Q. Epithelium-derived chemokines induce airway smooth muscle cell migration. Clin. Exp. Allergy 2009, 39, 1018–1026, doi:10.1111/j.1365-2222.2009.03238.x.
6. Verspohl, E.; Podlogar, J. LPS-induced proliferation and chemokine secretion from BEAS-2B cells. Pharmacol. Pharm. 2012, 3, doi:10.4236/pp.2012.32024.
7. Asutsa, J.; Flitt, J.; Bochner, B.S.; Schleimer, R.P. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. Am. J. Respir. Cell Mol. Biol. 1999, 20, 643–650, doi:10.1165/ajrcmb.20.4.3265.
8. Asutsa, J.; Sterbinsky, S.A.; Flitt, J.; Schiebert, L.M.; Bochner, B.S.; Schleimer, R.P. Phenotyping and cytokine regulation of the BEAS-2B human bronchial epithelial cell: Demonstration of inducible expression of the adhesion molecules VCAM-1 and ICAM-1. Am. J. Respir. Cell Mol. Biol. 1997, 17, 571–582, doi:10.1165/ajrcmb.17.5.2685.
13. Zu, Y.-x.; Lu, H.-y.; Liu, W.-w.; Jiang, X.-w.; Huang, Y.; Li, X.; Zhao, Q.-c.; Xu, Z.-h. Jiang Gui Fang activated intercapsular brown adipose tissue and induced epididymal white adipose tissue browning through the PPARγ/SIRT1-PGC1α pathway. *J. Ethnopharmacol.* **2020**, *248*, 112271, doi:10.1016/j.jep.2019.112271.

10. Wang, S.; Chen, L.; Leng, J.; Chen, P.; Fan, X.; Cheng, Y. Fragment ion diagnostic strategies for the comprehensive identification of chemical profile of Gui-Zhi-Tang by integrating high-resolution MS, multiple-stage MS and UV information. *J. Pharm. Biomed. Anal.* **2014**, *88*, 22–35, doi:10.1016/j.jpba.2014.05.013.

15. Kutsuwa, M.; Nakahata, N.; Kubo, M.; Hayashi, K.; Ohiizumi, Y. A comparative study of Kakkon-to and Keishi-to on prostaglandin E(2) release from rabbit astrocytes. *Phytomedicine* **1998**, *5*, 275–282, doi:10.1016/s0944-7113(98)80066-4.

12. Yoo, S.R.; Kim, Y.; Lee, M.Y.; Kim, O.S.; Seo, C.S.; Shin, H.K.; Jeong, S.J. Gyei-tang water extract exerts anti-inflammatory activity through inhibition of ERK and NF-κB pathways in lipopolysaccharide-stimulated RAW 264.7 cells. *BMC Complement. Altern. Med.* **2016**, *16*, 390, doi:10.1186/s12906-016-1366-8.

18. Zu, X.-F. Experimental study on the immunosuppressive effects of gui zhi tang. *Zhong Xi Yi Jie He Za Zhi* **1989**, *9*, 283–285, 262.

14. Fujiwara, H.; Han, Y.; Ebihara, K.; Awale, S.; Araki, R.; Yabe, T.; Matsumoto, K. Daily administration of yokukansan and keishito prevents social isolation-induced behavioral abnormalities and down-regulation of phosphorylation of neuroplasticity-related signaling molecules in mice. *BMC Complement. Altern. Med.* **2017**, *17*, 195, doi:10.1186/s12906-017-1710-7.

20. Motoo, Y.; Su, S.B.; Xie, M.J.; Mouru, H.; Taga, H.; Sawabu, N. Effect of herbal medicine keishi-to (Ti-45) and its components on rat pancreatic acinar cell injuries in vivo and in vitro. *Pancentology* **2001**, *1*, 102–109, doi:10.1159/000055801.

19. Zhang, Z.; Jiang, M.; Wei, X.; Shi, J.; Geng, Z.; Yang, S.; Fu, C.; Guo, L. Rapid discovery of chemical constituents and absorbed components in rat serum after oral administration of Paeonia-fuzi-zhong pill based on high-throughput HPLC-Q-TOF/MS analysis. *Chin. Med.* **2019**, *14*, 6, doi:10.1186/s31020-019-0227-z.

11. Lee, M.-K.; Kim, H.-W.; Kim, Y.; Lee, S.-H.; Jiang, H.-H.; Jung, H.-A.; Kim, S.-B.; Lee, S.-H.; Choe, J.-S.; Kim, J.-B. Profiling of flavonoid glycosides in fruits and leaves of jujube (*Zizyphus jujuba* var. inermis (Bunge) Rehder) using UPLC-DAD-QTOF/MS. *Korean J. Food Preserv.* **2016**, *23*, 1004–1011, doi:10.11002/kjfp.2016.23.7.1004.

21. Park, E.J.; Choi, J.; Park, Y.K.; Park, K. Oxidative stress induced by cerium oxide nanoparticles in cultured BEAS-2B cells. *Toxicology* **2008**, *245*, 90–100, doi:10.1016/j.tox.2007.12.022.

22. Gong, J.H.; Shin, D.; Han, S.Y.; Kim, J.L.; Kang, Y.H. Kaempferol suppresses eosinophil infiltration and airway inflammation in airway epithelial cells and in mice with allergic asthma. *J. Nutr.* **2012**, *142*, 47–56, doi:10.3945/jn.111.150748.

23. Matsukura, S.; Osakabe, Y.; Sekiguchi, A.; Inoue, D.; Kakihata, Y.; Funaki, T.; Yamazaki, Y.; Takayasu, H.; Tateno, H.; Kato, E.; et al. Overexpression of microRNA-155 suppresses chemokine expression induced by interleukin-13 in BEAS-2B human bronchial epithelial cells. *Allergol. Int.* **2016**, *65*, S17–S23, doi:10.1016/j.alleri.2016.04.018.

24. Jose, P.J.; Griffiths-Johnson, D.A.; Collins, P.D.; Walsh, D.T.; Moqbel, R.; Totty, N.F.; Truong, O.; Hsuan, J.J.; Williams, T.J. Eotaxin: A potent eosinophil chemoattractant cytokine in a guinea pig model of allergic airways inflammation. *J. Exp. Med.* **1994**, *179*, 881–887, doi:10.1084/jem.179.3.881.

26. Forssmann, U.; Ugucioni, M.; Loetscher, P.; Dahinden, C.A.; Langen, H.; Thelen, M.; Baggioni, M. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. *J. Exp. Med.* **1997**, *185*, 2171–2176, doi:10.1083/jem.185.12.2171.

27. Kitaura, M.; Suzuki, N.; Imai, T.; Takagi, S.; Suzuki, R.; Nakajima, T.; Hirai, K.; Nomiyama, H.; Yoshie, O. Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3. *J. Biol. Chem.* **1999**, *274*, 27975–27980, doi:10.1074/jbc.274.39.27975.

28. Provost, V.; Larose, M.C.; Langlois, A.; Rola-Pleszcynski, M.; Flamand, N.; Laviolette, M. CCL26/eotaxin-3 is more effective to induce the migration of eosinophils of asthmatics than CCL11/eotaxin-1 and CCL24/eotaxin-2. *J. Leukoc. Biol.* **2013**, *94*, 213–222, doi:10.1189/jlb.0212074.

29. Alam, R.; Stafford, S.; Forsythe, P.; Harrison, R.; Faubion, D.; Lett-Brown, M.A.; Grant, J.A. RANTES is a chemotactic and activating factor for human eosinophils. *J Immunol.* **1993**, *150*, 3442–3448.

30. Brand, K.H.; Ahout, I.M.; de Groot, R.; Warris, A.; Ferwerda, G.; Hermans, P.W. Use of MMP-8 and MMP-9 to assess disease severity in children with viral lower respiratory tract infections. *J. Med. Virol.* **2012**, *84*, 1471–1480, doi:10.1002/jmv.23301.

31. Phillips, P.G.; Birnby, L.M. Nitric oxide modulates caveolin-1 and matrix metalloproteinase-9 expression and distribution at the endothelial cell/tumor cell interface. *Am. J. Physiol. Lung Cell Mol. Physiol.* **2004**, *286*, L1055–L1065, doi:10.1152/ajplung.2001.281.6.L1444.

32. Proud, D.; Leigh, R. Epithelial cells and airway diseases. *Immunol. Rev.* **2011**, *242*, 186–204, doi:10.1111/j.1600-065X.2011.01033.x.
33. Nakajima, H.; Sano, H.; Nishimura, T.; Yoshida, S.; Iwashomo, I. Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J. Exp. Med. 1994, 179, 1145–1154, doi:10.1084/jem.179.4.1145.

34. Yeh, C.F.; Chang, J.S.; Wang, K.C.; Shieh, D.E.; Chiang, L.C. Water extract of Cinnamomum cassia Blume inhibited human respiratory syncytial virus by preventing viral attachment, internalization, and syncytium formation. J. Ethnopharmacol. 2013, 147, 321–326, doi:10.1016/j.jep.2013.03.010.

35. Shou, Q.; Lang, J.; Jin, L.; Fang, M.; Cao, B.; Cai, Y.; Xi, Z.; Qiu, F.; Li, C.; Cao, G.; et al. Total glucosides of peony improve ovalbumin-induced allergic asthma by inhibiting mast cell degranulation. J. Ethnopharmacol. 2019, 244, 112136, doi:10.1016/j.jep.2019.112136.

36. Wang, H.; Chang, B.; Wang, B. The effect of herbal medicine including astragalus membranaceus (fisch) bge, codonopsis pilosula and glycyrrhiza uralensis fisch on airway responsiveness. Zhonghua Iie He He Hu Xi Za Zhi 1998, 21, 287–288.

37. Khan, A.M.; Shahzad, M.; Raza Asim, M.B.; Imran, M.; Shabbir, A. Zingiber officinale ameliorates allergic asthma via suppression of Th2-mediated immune response. Pharm. Biol. 2015, 53, 359–367, doi:10.3109/13880209.2014.920396.

38. Ninave, P.B.; Patil, S.D. Antiasthmatic potential of Zizyphus jujuba Mill and Jujuboside B.—Possible role in the treatment of asthma. Respir. Physiol. Neurobiol. 2019, 260, 28–36, doi:10.1016/j.resp.2018.12.001.

39. Zhou, H.; Wu, Q.; Wei, L.; Peng, S. Paeoniflorin inhibits PDGF-BB-induced human airway smooth muscle cell growth and migration. Mol. Med. Rep. 2018, 17, 2660–2664, doi:10.3892/mmr.2017.8180.

40. Zhang, T.; Yang, Z.; Yang, S.; Du, J.; Wang, S. Immunoregulatory Effects of Paeoniflorin Exerts Anti-asthmatic Effects via Modulation of the Th1/Th2 Equilibrium. Inflammation 2015, 38, 2017–2025, doi:10.1007/s10753-015-1018-5.

41. Ram, A.; Mabalirajan, U.; Das, M.; Bhattacharya, I.; Dinda, A.K.; Gangal, S.V.; Ghosh, B. Glycyrrhizin alleviates experimental allergic asthma in mice. Int. Immunopharmacol. 2006, 6, 1468–1477, doi:10.1016/j.intimp.2006.04.020.

42. Ma, C.; Ma, Z.; Liao, X.L.; Liu, J.; Fu, Q.; Ma, S. Immunoregulatory effects of glycyrrhizic acid exerts anti-asthmatic effects via modulation of Th1/Th2 cytokines and enhancement of CD4(+)CD25(+)Foxp3+ regulatory T cells in ovalbumin-sensitized mice. J. Ethnopharmacol. 2013, 148, 755–762, doi:10.1016/j.jep.2013.04.021.

43. Hocaoglu, A.B.; Karaman, O.; Erge, D.O.; Erbil, G.; Yilmaz, O.; Bagriyanik, A.; Uzuner, N. Glycyrrhizin and long-term histopathologic changes in a murine model of asthma. Curr. Ther. Res. Clin. Exp. 2011, 72, 250–261, doi:10.1016/j.curtheres.2011.11.002.

44. Yocum, G.T.; Hwang, J.J.; Mikami, M.; Danielsson, J.; Kuforiji, A.S.; Emala, C.W. Ginger and its bioactive component 6-shogaol mitigate lung inflammation in a murine asthma model. Am. J. Physiol. Lung Cell Mol. Physiol. 2020, 318, L296–L303, doi:10.1152/ajplung.00249.2019.

45. Li, Z.; Liu, Z.; Uddand Rao, V.V.S.; Ponnum, P.; Balakrishnan, S.; Brahmanaidu, P.; Vadivukkarasi, S.; Ganapathy, S. Asthma-Alleviating Potential of 6-Gingerol: Effect on Cytokines, Related mRNA and c-Myc, and NFAT1 Expression in Ovalbumin-Sensitized Asthma in Rats. J. Environ. Pathol. Toxicol. Oncol. 2019, 38, 41–50, doi:10.1615/JEnvironPatholToxicolOncol.2018027172.

46. Hwang, Y.H.; Ma, J.Y. Preventive Effects of an UPLC-DAD-MS/MS Fingerprinted Hydroalcoholic Extract of Citrus aurantium in a Mouse Model of Ulcerative Colitis. Planta Med. 2018, 84, 1101–1109, doi:10.1055/a-0046-0451.